Fabry's disease and psychosis: causality or coincidence? by Gairing, S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2011
Fabry’s disease and psychosis: causality or coincidence?
Gairing, S; Wiest, R; Metzler, S; Theodoridou, A; Hoff, P
Abstract: A 21-year-old female with Fabry’s disease (FD) presented acute psychotic symptoms such as
delusions, auditory hallucinations and formal thought disorders. Since the age of 14, she had suffered
from various psychiatric symptoms increasing in frequency and intensity. We considered the differen-
tial diagnoses of prodromal symptoms of schizophrenia and organic schizophrenia-like disorder. Rou-
tine examinations including cognitive testing, electroencephalography and structural magnetic resonance
imaging revealed no pathological findings. Additional structural and functional imaging demonstrated a
minor CNS involvement of FD, yet without functional limitations. In summary our examination results
support the thesis that in the case of our patient a mere coincidence of FD and psychotic symptoms is
more likely than a causal connection. Copyright © 2011 S. Karger AG, Basel.
DOI: 10.1159/000322794
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-57924
Published Version
Originally published at:
Gairing, S; Wiest, R; Metzler, S; Theodoridou, A; Hoff, P (2011). Fabry’s disease and psychosis: causality
or coincidence? Psychopathology, 44(3):201-204. DOI: 10.1159/000322794
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Case Report 
 Psychopathology 2011;44:201–204 
 DOI: 10.1159/000322794 
 Fabry’s Disease and Psychosis:
Causality or Coincidence? 
 S. Gairing  a    R. Wiest  b    S. Metzler  a    A. Theodoridou  a    P. Hoff  a   
 a   Department of General and Social Psychiatry, Psychiatric University Hospital Zurich,  Zurich , and
 b   Institute of Diagnostic and Interventional Neuroradiology, University of Bern, Inselspital,  Bern , Switzerland 
 Introduction 
 Fabry’s disease (FD) is an X-linked lysosomal storage 
disease, the incidence of which has been underestimated 
and is likely to be as high as 1 in 3,100 male babies  [1] . The 
deficiency in   -galactosidase A results in accumulation 
of glycosphingolipids in many tissues and cell types. This 
process leads to progressive organ dysfunction and thus 
typical clinical signs of the disease. In early stages, the 
patients present with burning pain in hands and feet, hy-
pohydrosis, abdominal pain, postprandial diarrhea and 
poor growth. In later stages, life-threatening complica-
tions like renal insufficiency as well as cardiac and cere-
brovascular incidents may occur. Ever since its introduc-
tion in 2001, enzyme replacement therapy has helped to 
improve patients’ life expectancy and quality of life by 
reducing tissue deposition and by easing clinical symp-
toms like pain and acroparesthesia.
 These neurological symptoms are mainly held respon-
sible for the most common psychiatric manifestation in 
these patients, depressive syndromes, which are gener-
ally regarded as adjustment disorders  [2–4] . Our litera-
ture research has revealed only 2 cases of patients with 
FD and a concomitant psychosis which were discussed 
controversially  [5, 6] . 
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 Abstract 
 A 21-year-old female with Fabry’s disease (FD) presented 
acute psychotic symptoms such as delusions, auditory hal-
lucinations and formal thought disorders. Since the age of 
14, she had suffered from various psychiatric symptoms 
 increasing in frequency and intensity. We considered the 
 differential diagnoses of prodromal symptoms of schizo-
phrenia and organic schizophrenia-like disorder. Routine 
 examinations including cognitive testing, electroencepha-
lography and structural magnetic resonance imaging re-
vealed no pathological findings. Additional structural and 
functional imaging demonstrated a minor CNS involvement 
of FD, yet without functional limitations. In summary our ex-
amination results support the thesis that in the case of our 
patient a mere coincidence of FD and psychotic symptoms 
is more likely than a causal connection. 
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 We would like to present the case of a young woman 
with FD and psychotic symptoms, in order to further de-
velop this debate and answer the question of the relation-
ship between FD and the psychotic symptoms: was it cau-
sality or coincidence? 
 Case Report 
 A 21-year-old female was admitted to the Psychiatric Univer-
sity Hospital of Zurich for the first time with acute psychotic 
symptoms. She was in an agitated state and convinced she had to 
die the same night. Further prominent symptoms included delu-
sions of reference, persecutory delusions and auditory hallucina-
tions. The patient had suffered from these symptoms for several 
hours before she had called a friend for help, who accompanied 
her to the hospital. The delusional beliefs and auditory hallucina-
tions remitted within 24 h, leaving the patient with delusions of 
reference and formal thought disorders, i.e. circumstantial think-
ing, loosening of associations and thought blocking. These symp-
toms had first occurred at the age of 16 and, although becoming 
more intense and frequent, had never lasted for longer than 24 h. 
Beforehand she had suffered from depressed mood and anxiety 
for about 2 years. At the age of 15 she had become profoundly in-
terested in Catholicism and has claimed to feel a strong connec-
tion to god ever since.
 Her medical history revealed that the diagnosis of FD had been 
established 9 years ago when the patient herself and her 9 siblings 
were screened due to the diagnosis of FD in one of her brothers. 
She had received enzyme replacement therapy with agalsidase   
(Replagal TM ) every fortnight and displayed only a mild phenotype 
of the lysosomal storage disease. She complained about pain, ac-
roparesthesia, hypohydrosis, abdominal pain, postprandial diar-
rhea and fatigue. Six of her 9 siblings were affected by FD as well, 
one of her sisters suffered from similar psychiatric symptoms and 
has been hospitalized once. 
 In the case of our patient, treatment was initiated with daily 
doses of risperidone 1 mg at bedtime. An attempt to increase the 
dosage gradually to 2 mg failed when the patient developed side 
effects such as muscle stiffness and sedation and refused to con-
tinue the medication. Therapy was switched to aripiprazole, start-
ing at a dosage of 5 mg in the morning. The dosage was increased 
to 10 mg within a week. The patient reported an improvement of 
her formal thought disorders. When developing a severe gastro-
intestinal infection, the patient demanded discontinuation of
aripiprazole. However, the psychiatric symptoms gradually im-
proved over the following weeks. Difficulties in concentration 
persisted. 
 During her stay at our hospital, additional examinations were 
carried out. The results of laboratory screening and urine toxicol-
ogy screen were normal. Electroencephalography (EEG) and con-
ventional brain magnetic resonance imaging (MRI) revealed no 
pathological findings. 
 Furthermore a battery of cognitive tests including measures 
of processing speed, attention, memory and executive function 
were administered when most positive symptoms had abated 
and the patient was in a stable condition. As shown in  table 1 , 
the patient’s premorbid intelligence level was estimated to be at 
average level, whereas at the time of the testing mild cognitive 
impairments were found in the domain of attention, processing 
speed and measures of cognitive f lexibility. The effects were 
considered unlikely to occur due to medication as the daily dos-
age was low at the  time of testing (aripiprazole 5 mg, lorazepam
0.75 mg).
 As CNS involvement is known to be a possible major burden 
in FD patients and suspected to be a possible cause for the symp-
toms described, our patient was subjected to structural and func-
tional MRI including diffusion tensor imaging, arterial spin la-
beling, time-of-flight angiography  [7] and magnetic resonance 
spectroscopy. In structural MRI no abnormalities were found. 
Cerebral blood flow as measured by arterial spin labeling was 
symmetric and without pathological findings. In time-of-flight 
angiography the diameter of the basilar artery was 2.8 mm and 
thus pathological  [8] . By visual inspection the cerebral arteries 
were normal. In spectroscopy there was no focal reduction of 
NAA or NAA/CR ratio and no asymmetry. An increase for cho-
line by 10% was found in the left centrum semiovale. Neither lac-
tate nor pathologic macromolecules were found. Diffusion tensor 
imaging multiregion analysis revealed no focal pathological find-
ings of fractional anisotropy and apparent diffusion coefficient 
values (= 1/mean diffusivity) except for minor asymmetries found 
in the centrum semiovale.
Table 1. C ognitive tests
Test and reference Domain Test score 
on t-scale
MWT premorbid verbal intelligence 50
ZVT processing speed 39
FAIR attention 39
TAP phasic alertness attention 36
TAP tonic alertness attention 30
TAP divided attention attention 26
VLMT verbal learning verbal learning 51
VLMT delayed recall verbal memory 47
Digit span (WMS-R) verbal working memory 44
Block span (WMS-R) visuospatial working memory 56
Stroop test attention, executive function 40–50
RWT S-words phonematic fluency 58
RWT animals, food categorial fluency 45
5-Point test figural fluency <40
Trail making A and B speed, cognitive flexibility 37
CKV executive function >40
M WT = Mehrfachwahl-Wortschatztest; ZVT = Zahlenver-
bin dungstest; FAIR = Frankfurter Aufmerksamkeitsinventar; 
TAP = Testbatterie zur Aufmerksamkeitsprüfung; VLMT = Ger-
man Version of the California Verbal Learning Test, ‘Verbaler 
Lern- und Merkfähigkeitstest’; WMS-R = Wechsler Memory 
Scale-Revised; RWT = Regensburger Wortflüssigkeits-Test;
CKV = computerized and adapted version of the Wisconsin Card 
Sorting Test, ‘Computergestütztes Kartensortierverfahren’.
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 Discussion 
 In the case of our patient we considered the differential 
diagnoses of organic schizophrenia-like disorder and 
prodromal symptoms of schizophrenia. The psycho-
pathological findings were nonspecific. No hints for or-
ganic involvement were found in conventional MRI and 
EEG examinations. Concerning the neuropsychological 
testing, deficits in attention, working memory and exe-
cutive function considered to be typical, but not patho-
gnomonic, for schizophrenia  [9] were partly found in our 
patient (alertness, measures of selective and divided at-
tention). Therefore and due to the heterogeneity of endo-
phenotypes in schizophrenia, a clear diagnosis could not 
be derived from the results of the routine examinations 
conducted. 
 According to DSM IV and ICD 10, the psychotic syn-
drome is to be classified as an organic mental disorder 
when a systemic disease affecting the CNS is present. On 
the other hand, one may argue that typical features of a 
developing schizophrenic disorder were present: in-
creased stress vulnerability due to a family history of vio-
lence, the course of the disease with steadily increasing 
frequency and intensity of symptoms over a period of sev-
eral years. Retrospectively the patient may have been in 
an early prodromal phase since first symptoms like de-
pression and anxiety occurred at the age of 14. In the 
course of disease, attenuated psychotic symptoms such as 
hyperreligiosity and brief limited intermittent psychotic 
episodes appeared. Because of the duration of delusional 
and hallucinatory symptoms the diagnostic criteria for 
duration of these symptoms in schizophrenia (ICD 10) or 
schizophreniform disorder (DSM IV) were not met. Both 
diagnostic manuals require presence of these symptoms 
with a duration  6 4 weeks. Our patient’s syndrome meets 
some of the major ultra-high-risk criteria  [9] and meets 
the diagnostic criteria for a late prodromal state  [10] . 
 In order to clarify the diagnosis, we collected further 
structural and functional cerebral imaging results. Alto-
gether, these examinations revealed mild affection of the 
brain, most likely due to FD. The most common involve-
ment of the CNS in FD is cerebral vasculopathy caused by 
deposition of neutral glycosphingolipids in the vascular 
endothelium  [11] . The mechanical weakening of the vessel 
wall caused by these depositions frequently results in dila-
tation and tortuosity of larger vessels  [12] . Concerning the 
macroangiopathic analysis conducted by time-of-flight 
angiography, the basilar artery diameter of 2.8 mm in our 
patient was pathological: Fellgiebel et al. [8] had found the 
mean basilar artery diameter to be significantly enlarged 
in women with FD compared to women of a normal con-
trol group (patients 3.0 mm, SD 0.33 mm; controls 2.4 mm, 
SD 0.33 mm, p  ^  0.0005). Currently chronic cerebral hy-
poperfusion is regarded as a necessary condition for the 
development of white matter lesions  [13, 14] . The preva-
lence of acute cerebral hypoperfusion as in ischemic stroke 
and transient ischemic attacks is significantly higher in 
FD patients and a major form of disease  [15] . Moreover, 
autopsy studies have shown cerebral glycolipid deposition 
of uncertain clinical significance in specific neuronal 
populations  [16, 17] . In regard to CNS manifestations, the 
effect of enzyme replacement therapy on white matter le-
sions and on the prevalence of ischemic cerebrovascular 
events has not yet been demonstrated. Restricted access of 
infused enzyme to the vascular system beyond the endo-
thelial cells  [18] is likely to reduce potential clinical effects 
on CNS involvement. In our patient, asymmetric findings 
in the centrum semiovale in choline measurement in mag-
netic resonance spectroscopy hint at an ongoing neurode-
generative process. As no microangiopathic changes were 
found in this region, this may be a result of accumulation 
of neutral glycosphingolipids.
 Altogether, the imaging findings demonstrated a mi-
nor CNS involvement with vessel dilatation and neurode-
generative findings in the right centrum semiovale, pos-
sibly due to glycolipid deposition. In a previous report on 
psychosis in a patient with FD, brain MRI had revealed 
small hyperintense spots in the right thalamus, midbrain 
and corona radiata on T 2 -weighted imaging. The fact that 
these lesions had been absent in previous scans was taken 
as a hint for a connection between psychotic symptoms 
and thalamic lesions due to FD  [6] . In such cases, where 
the connection between the lesions and clinical symp-
toms is plausible, the diagnosis of organic schizophrenia-
like disorder seems to be justified. In our patient, how-
ever, the pathologic findings had not yet resulted in func-
tional limitations associated with schizophreniform 
disorder or schizophrenia.
 In summary, the patient’s symptoms were unlikely to 
be of predominantly organic origin although mild CNS 
involvement of FD is present. The categorical diagnostic 
systems do not provide a differentiated diagnostic ap-
proach to such a potentially multifactorial case. The fu-
ture development of these systems towards a dimensional 
model allowing for multiple causes and psychopathologic 
dimensions would add to a more facetted understanding 
and personalized treatment of such cases. In summary, 
our examination results support the hypothesis that a 
mere coincidence of FD and psychotic symptoms in this 
case is more likely than a causal connection. 
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